Not registered yet? Please contact our project manager Dr. Sara Stöber . This area is only for members of the research consortium.

News

Event on Monday, 05 December 2022

First public QSPainRelief Masterclass

Excited to announce the first public QSPainRelief Masterclass in the Barcelona Biomedical Research Park (PRBB building of the University Pompeu Fabra) in Barcelona on Monday, 5 December 2022, from 2:00-4:30 pm, featuring a talk by Prof. Dr. Liesbeth De Lange about the role of smart data in pharmacokinetics and pharmacodynamics, and a talk by Prof. Dr. André Mouraux about biomarkers of nociception on the way to personalised management of chronic pain. Bring your colleagues and trainees – and spread the word!

More news

Events

05-07 December 2022

See you soon in Barcelona!

We can’t wait to catch up with the entire QSPainRelief consortium at the 4th General Assembly (GA) Meeting in Barcelona from 5-7 December 2022. Science- and fun-filled days are ahead, starting with two Masterclass lectures at the Barcelona Biomedical Research Park (PRBB), followed by a welcome dinner at the hotel in Castelldefels, an early career scientists’ poster session (including an award for the best poster), updates from all work packages, and lots of discussions.

More events

Resources

Personalise and maximize pain relief for individuals suffering from chronic pain

Summary Statement

10 institutions in Europe and the USA collaborate for the next 5 years to help patients suffering from chronic pain. QSPainRelief aims to develop effective drug combination treatments for the improved relief of chronic pain. A quantitative systems pharmacology (QSP) mathematical modelling approach will be used to identify and validate more effective therapeutic interventions by smart combinations of existing drugs. The ultimate goal is to personalise and maximize pain relief for individuals suffering from chronic pain while diminishing side effects.

Learn more

Objectives

  • Consolidating cutting-edge treatment models for chronic pain
  • Summary Statement
  • Validating novel combinational therapies preclinically in vitro and in vivo
  • Conducting clinical studies to detect functional biomarkers
  • Improving the clinical guidelines for pain relief in stratified patient groups
  • Personalising pain relief treatment for each patient
  • Improving the scientific understanding of chronic pain regarding age, sex, disease and genetic factors

Impact

  • Novel concepts of combinational pain relief therapies
  • Improved efficacy and acceptability in the clinic
  • Effective stratification of patients with respect to age, sex, disease and genotype
  • Personalised treatment with unswerving benefits for patients
  • Unique knowledge gain and innovation opportunities

Project partners